{
  "docId": "019de071-e0d6-76fb-ba84-d69d61ac5ee5",
  "docSlug": "1773642d94b9dc79507cf930970e5456",
  "documentTitle": "Certara | Investor Day Presentation Deck | 91 slides",
  "authorId": "certara",
  "authorName": "Certara",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 91,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-e0d6-76fb-ba84-d69d61ac5ee5/12",
  "deckHref": "/decks/019de071-e0d6-76fb-ba84-d69d61ac5ee5",
  "deckJsonHref": "/decks/019de071-e0d6-76fb-ba84-d69d61ac5ee5.json",
  "deckAnchorHref": "/decks/019de071-e0d6-76fb-ba84-d69d61ac5ee5#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.5,
        "x": 0.05,
        "y": 0.145
      },
      "kind": "chart",
      "text": "Complexity vs Cost growth curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "453b7274-0ba1-4c30-8a91-c9b024530d26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.38,
        "x": 0.59,
        "y": 0.175
      },
      "kind": "list",
      "text": "Cost of development grows with complexity of compound; Clinical phase times are increasing; Biologics comprise 43% of the R&D pipeline; Complex generics also pose development challenges",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c69e0a83-c150-4b0a-b523-5efdab4d85f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.55,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Drug R&D grows in complexity and cost",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea633c11-86a4-4f1d-a53d-a26ac731711f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "4e374793-febe-464b-845f-af228da3d04a",
      "evidence": "chart/line: Complexity vs Cost growth curve",
      "confidence": 0.7
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "c34a4032-1921-4c14-b85c-658d6e024326",
      "evidence": "list/bullet: Cost of development grows with complexity of compound; Clinical phase times are increasing; Biologics comprise 43% of the R&D pipeline; Complex generics also pose development challenges",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "3febb1b1-76b6-4466-a201-7c24a01e3217",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "Pain points in clinical phase and complexity of drug R&D are highlighted",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 12,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "aefb73c8-4528-41b5-be1f-4d7ee4e62081",
      "evidence": "The deck highlights the costs and complexities of traditional drug R&D",
      "position": 0,
      "objective": "What are the costs of not using biosimulation?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}